featured
AAN 2021: Tolebrutinib Reduces Brain Lesions in Highly Active Relapsing Multiple Sclerosis
The investigational agent will soon be studied in phase III trials
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.